A new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Solove Research Institute (OSUCCC – James) has identified a protein within certain immune cells that is required for optimal immune responses to cancer. The findings, reported in the journal Science Advances, also suggest that the protein might be useful for predicting which cancer patients are less likely to respond to the form of therapy called immune checkpoint blockade.
- Berkeley Lab science snapshots
- New treatment targets found for blinding retinal disease
- KIST finds clue to improve artificial vision for patients with retinitis pigmentosa
- How to boost tips and donations with the dueling preference approach
- UT southwestern levels the playing field for testicular cancer patients